{"id":109289,"date":"2026-06-08T10:48:19","date_gmt":"2026-06-08T05:18:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=109289"},"modified":"2026-06-08T10:48:21","modified_gmt":"2026-06-08T05:18:21","slug":"alembic-pharma-share-price-canada-jv-usfda-haloperidol-june-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-canada-jv-usfda-haloperidol-june-2026\/","title":{"rendered":"Alembic Pharma Share Price Climbs on June 8, 2026 After Canada JV with Difgen Holdings and USFDA Approval for Haloperidol Tablets"},"content":{"rendered":"
<\/div>\n

Alembic Pharma share price June 8 2026: Rs 744.95, +0.89%. High Rs 754.15. 52W High Rs 1,107.90. Canada JV: 45% stake. USFDA: Haloperidol ($27M market).<\/em><\/p>\n

Alembic Pharma<\/a> share price gained 0.89% to Rs 744.95 on June 8, 2026, outperforming a weak broader market, after two positive corporate developments: the signing of a shareholders’ agreement for a 45% stake in a Canadian corporation (a joint venture with Difgen Holdings to develop and market pharmaceutical products in Canada), and the receipt of a final US FDA approval for Haloperidol Tablets with an estimated US market size of $27 million.<\/p>\n

The Alembic Pharma share price touched an intraday high of Rs 754.15, gaining Rs 6.55 from its previous close of Rs 738.40. Both catalysts were announced within two days of each other (June 5-6, 2026) and collectively improve the company’s international revenue pipeline, adding near-term optimism at a time when Alembic Pharma has been trading well below its 52-week high.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Parameter<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
NSE Symbol<\/td>\nAPLLTD<\/td>\n<\/tr>\n
CMP (June 8, 2026)<\/td>\nRs 744.95<\/td>\n<\/tr>\n
Previous Close<\/td>\nRs 738.40<\/td>\n<\/tr>\n
Change<\/td>\n+0.89% (+Rs 6.55)<\/td>\n<\/tr>\n
Open<\/td>\nRs 742.75<\/td>\n<\/tr>\n
Intraday High<\/td>\nRs 754.15<\/td>\n<\/tr>\n
Intraday Low<\/td>\nRs 732.65<\/td>\n<\/tr>\n
52-Week High<\/td>\nRs 1,107.90<\/td>\n<\/tr>\n
52-Week Low<\/td>\nRs 635.80<\/td>\n<\/tr>\n
Market Cap (approx.)<\/td>\nRs 14,514 Cr<\/td>\n<\/tr>\n
P\/E Ratio (TTM)<\/td>\n~22.62<\/td>\n<\/tr>\n
Promoter Holding<\/td>\n69.74%<\/td>\n<\/tr>\n
Sector<\/td>\nPharmaceuticals<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

3 Stocks Building Serious Momentum Right Now<\/p>\n

When Univest analysts<\/strong> identify high-conviction stock opportunities, investors pay attention.<\/em><\/p>\n

Our research team has shortlisted the Top Stocks to Buy<\/strong> based on current market momentum, sector trends & growth potential for 2026.<\/p>\n